VITILIGO: WHAT’S OLD, WHAT’S NEW?

Authors

  • Maja Dimova University Clinic for Dermatology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia
  • Viktor Simeonovski University Clinic for Dermatology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia
  • Julija Mitrova Telenta University Clinic for Dermatology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia
  • Nora Pollozhani University Clinic for Dermatology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia

Keywords:

Keywords: vitiligo; melanocyte destruction; microbiome; neural hypothesis; JAK inhibitors

Abstract

Vitiligo is a chronic, inflammatory, autoimmune disorder resulting from a selective destruction of melanocytes and the appearance of depigmented skin patches. It affects all ethnic groups and genders equally, with a slight female predominance. It is estimated that approximately 0.5-2% of the global population suffer from vitiligo, making this dermatosis the most common pigmentation disorder. Vitiligo is a complex disease with complex etiology and pathogenesis. It is currently accepted that genetic predisposition and environmental factors lead to melanocyte oxidative stress, and activation of abnormal immune response, but the overall contribution of each of these processes remains insufficiently clear.

Historically, vitiligo was recognized in ancient times, with evidence found in ancient Egyptian, Greek, and Indian texts. Early interpretations associated this skin disease with divine punishment or contagion, leading to quarantines and stigmatization. Today, vitiligo is classified as an autoimmune disease, with autoimmune attack on melanocytes considered the primary factor leading to the appearance of depigmented macules. The skin and gut microbiome and neural hypothesis have recently gained attention as emerging factors in the pathogenesis of vitiligo.

The treatment of vitiligo remains a significant challenge. It includes local and systemic immunosuppressives, phototherapy, surgical techniques, as well as other therapeutic approaches, including traditional medicine, camouflage, depigmentation, and psychological interventions. However, vitiligo has a long treatment cycle, and all current treatments provide only short-term benefits, with relapse of the disease being common once treatments are discontinued. In recent years targeted therapies such as JAK inhibitors are actively being developed.

References

Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015 Jul 4;386(9988):74–84. doi:10.1016/S0140 6736(14)60763 7

Bibeau K, Pandya AG, Ezzedine K, Jones H, Gao J, Lindley A, Harris JE. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1831–1844. doi:10.1111/jdv.18257

Amer AA, Gao XH. Quality of life in patients with vitiligo: an analysis of the dermatology life quality index outcome over the past two decades. Int J Dermatol. 2016 Jun;55(6):608–614. doi:10.1111/ijd.13198

Bae JM, Lee SC, Kim TH, Yeom SD, Shin JH, Lee WJ, et al. Factors affecting quality of life in patients with vitiligo: a nationwide study. Br J Dermatol. 2018 Jan;178(1):238–244. doi:10.1111/bjd.15560

Yang TT, Lee CH, Lan CE. Impact of Vitiligo on Life Quality of Patients: Assessment of Currently Available Tools. Int J Environ Res Public Health. 2022 Nov 13;19(22):14943. doi:10.3390/ijerph192214943

Millington GW, Levell NJ. Vitiligo: the historical curse of depigmentation. Int J Dermatol. 2007 Sep;46(9):990–995. doi:10.1111/j.1365 4632.2007.03226.x

Prasad PV, Bhatnagar VK. Medico historical study of “Kilasa” (vitiligo/leucoderma) a common skin disorder. Bull Indian Inst Hist Med Hyderabad. 2003 Jul Dec;33(2):113–127.

Arcos Burgos M, Parodi E, Salgar M, Bedoya E, Builes J, Jaramillo D, et al. Vitiligo: complex segregation and linkage disequilibrium analyses with respect to microsatellite loci spanning the HLA. Hum Genet. 2002 Apr;110(4):334–342. doi:10.1007/s00439 001 0719 4

Chang WL, Lee WR, Kuo YC, Huang YH. Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention. Front Cell Dev Biol. 2021 Dec 14;9:797026. doi:10.3389/fcell.2021.797026

Matarrese P, Puglisi R, Mattia G, Samela T, Abeni D, Malorni W. An Overview of the Biological Complexity of Vitiligo. Oxid Med Cell Longev. 2024 Dec 19;2024:3193670. doi:10.1155/2024/3193670

Liu X, Liu J. Vitiligo: are microbes to blame? Biosci Microbiota Food Health. 2025;44(1):16–25.

Marchioro HZ, Silva de Castro CC, Fava VM, Sakiyama PH, Dellatorre G, Miot HA. Update on the pathogenesis of vitiligo. An Bras Dermatol. 2022 Jul Aug;97(4):478–490. doi:10.1016/j.abd.2022.03.002

Nazzaro G. Vitiligo: historical perspectives and the evolution of treatment. J Dermatol Treat. 2017;28(1):23–28. doi:10.1080/09546634.2016.1186328

Gauthier Y, Bérard F. Historical perspectives of vitiligo and leprosy: From the Middle Ages to modern times. Int J Dermatol. 2015;54(9):1030–1037. doi:10.1111/ijd.12929

Kundu RV, Mhlaba JM, Rangel SM, Le Poole IC. The convergence theory for vitiligo: a reappraisal. Exp Dermatol. 2019 Jun;28(6):647–655. doi:10.1111/exd.13925

Finkel TH, Bourke EJ. Genetic and immune mechanisms in vitiligo. J Invest Dermatol. 2020 Jul;140(7):1325–1334. doi:10.1016/j.jid.2019.12.013

Rees JL, Laddha SD. Genetics of vitiligo: Theories and insights. Br J Dermatol. 2017 Apr;176(4):1275–1284. doi:10.1111/bjd.15034

Yang S, et al. Genetic and epigenetic factors in vitiligo: A review of molecular mechanisms. Front Genet. 2019;10:907. doi:10.3389/fgene.2019.00907

Faraj S, Kemp EH, Gawkrodger DJ. Patho immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factors. Clin Exp Immunol. 2022 Jan 28;207(1):27–43. doi:10.1093/cei/ixab107

Manga P, Elbuluk N, Orlow SJ. Recent advances in understanding vitiligo. F1000Res. 2016 Sep 6;5:F1000 Faculty Rev 2234. doi:10.12688/f1000research.9280.1

Huggins RH, Davis LA. The role of the immune system in vitiligo. J Dermatol Sci. 2017 Feb;85(2):81–89. doi:10.1016/j.jdermsci.2016.11.008

Harris JE. Chemical Induced Vitiligo. Dermatol Clin. 2017 Apr;35(2):151–161. doi:10.1016/j.det.2016.11.006

Ghosh S, Mukhopadhyay S. Chemical leucoderma: Indian scenario, prognosis, and treatment. Indian J Dermatol. 2010 May Jun;55(3):250–254. doi:10.4103/0019 5154.68223

Goldstein NB, Koster MI, Hoaglin LG, Spoelstra NS, Kechris KJ, Robinson SE, Robinson WA, Roop DR, Norris DA, Birlea SA. Narrow Band Ultraviolet B Treatment for Human Vitiligo Is Associated with Proliferation, Migration, and Differentiation of Melanocyte Precursors. J Invest Dermatol. 2015 Aug;135(8):2068–2076. doi:10.1038/jid.2015.112

Zhang X, Lei L, Jiang L, Fu C, Huang J, Hu Y, Zhu L, Zhang F, Chen J, Zeng Q. Characteristics and pathogenesis of Koebner phenomenon. Exp Dermatol. 2023 Apr;32(4):310–323. doi:10.1111/exd.14628

Shin JU, Roh MR, Lee JH. Vitiligo following intense pulsed light treatment. J Dermatol. 2010 Jul;37(7):674–676. doi:10.1111/j.1346 8138.2010.00988.x

Shreberk Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: A systematic review. J Am Acad Dermatol. 2017 Apr;76(4):745–753.e19. doi:10.1016/j.jaad.2016.12.034

Qi F, Liu F, Gao L. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review. Front Immunol. 2021 Nov 18;12:790125. doi:10.3389/fimmu.2021.790125

Inoue S, Suzuki T, Sano S, Katayama I. JAK inhibitors for the treatment of vitiligo. J Dermatol Sci. 2024 Mar;113(3):86–92. doi:10.1016/j.jdermsci.2023.11.008

Karagaiah P, Schwartz RA, Lotti T, Wollina U, Grabbe S, Goldust M. Biologic and targeted therapeutics in vitiligo. J Cosmet Dermatol. 2023 Jan;22(1):64–73. doi:10.1111/jocd.15358

Bertolani M, Rodighiero E, de Felici Del Giudice MB, Lotti T, Feliciani C, Satolli F. Vitiligo: What’s old, what’s new. Dermatol Rep. 2021 Sep 15;13(2):9142. doi:10.4081/dr.2021.9142

Zeeuwen PL, Kleerebezem M, Timmerman HM, Schalkwijk J. Microbiome and skin diseases. Curr Opin Allergy Clin Immunol. 2013 Oct;13(5):514–520. doi:10.1097/ACI.0b013e328365a3da

Ni Q, Ye Z, Wang Y, Chen J, Zhang W, Ma C, Li K, Liu Y, Liu L, Han Z, et al. Gut microbial dysbiosis and plasma metabolic profile in individuals with vitiligo. Front Microbiol. 2020;11:592248. doi:10.3389/fmicb.2020.592248

Lu H, Xu J, Hu Y, Luo H, Chen Y, Xie B, Song X. Differences in the skin microbial community between patients with active and stable vitiligo based on 16S rRNA gene sequencing. Australas J Dermatol. 2021;62:e516–e523. doi:10.1111/ajd.13563

Mahmud MR, Akter S, Tamanna SK, Mazumder L, Esti IZ, Banerjee S, Akter S, Hasan MR, Acharjee M, Hossain MS, et al. Impact of gut microbiome on skin health: gut‐skin axis observed through the lenses of therapeutics and skin diseases. Gut Microbes. 2022;14:2096995. doi:10.1080/19490976.2022.2096995

Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E. Dysbiosis and the immune system. Nat Rev Immunol. 2017;17:219–232. doi:10.1038/nri.2016.142

Luan M, Niu M, Yang P, Han D, Zhang Y, Li W, He Q, Zhao Y, Mao B, Chen J, et al. Metagenomic sequencing reveals altered gut microbial compositions and gene functions in patients with non segmental vitiligo. BMC Microbiol. 2023;23:265. doi:10.1186/s12866 023 02914 9

Doğan Z, Özdemir P, Ekşioğlu M, Filik L. Relationship between Helicobacter pylori infection and vitiligo: a prospective study. Am J Clin Dermatol. 2014 Oct;15(5):457–462. doi:10.1007/s40257 014 0097 8

Bakry OA, Basha M, El Hefnawy S, Mekkawy S. Relationship between Disease Activity and Helicobacter pylori Infection in Patients with Vitiligo. Indian Dermatol Online J. 2018 Jan Feb;9(1):59–61. doi:10.4103/ijdvl.ijdvl_282_17

Rifaioğlu EN, Aydoğan F. Investigation Into The Frequency Of Helicobacter pylori Infection With Carbon 14 Urea Breath Test In Patients With Vitiligo. Turk J Med Sci. 2014;44(6):1075–1080. doi:10.3906/sag 1401 30

Akbayir N, Gökdemir G, Mansur T, Sökmen M, Gündüz S, Alkim C, Barutcuoğlu B, Erdem L. Is there any relationship between hepatitis C virus and vitiligo? J Clin Gastroenterol. 2004 Oct;38(9):815–817. doi:10.1097/01.MCG.0000139052.74801.98

Fawzy MM, Hammad NM, Sharaf AL, Khattab F. Hepatitis C virus infection could be a risk factor for adult onset vitiligo in Egyptian patients: A cross sectional study. J Cosmet Dermatol. 2022 Oct;21(10):4983–4989. doi:10.1111/jocd.14946

Grimes PE, Sevall JS, Vojdani A. Cytomegalovirus DNA identified in skin biopsy specimens of patients with vitiligo. J Am Acad Dermatol. 1996 Jul;35(1):21–26. doi:10.1016/S0190 9622(96)90490 9

Zhuang T, Yi X, Chen J, et al. Intracellular virus sensor MDA5 exacerbates vitiligo by inducing the secretion of chemokines in keratinocytes under virus invasion. Cell Death Dis. 2020;11:453. doi:10.1038/s41419 020 2665 z

Seneschal J, Boniface K. Vitiligo: Current Therapies and Future Treatments. Dermatol Pract Concept. 2023 Dec 1;13(4S2):e2023313S. doi:10.5826/dpc.1304a27

Sritanyarat T, Wongpraparut C, Jansuwan N, Yothachai P, Nuntawisuttiwong N, Silpa Archa N. Outcomes of autologous non cultured melanocyte keratinocyte transplantation in vitiligo and nevus depigmentosus. J Dermatolog Treat. 2022 Mar;33(2):935–940. doi:10.1080/09546634.2021.1962230

Rathod DG, Muneer H, Masood S. Phototherapy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Feb 16. doi:10.48550/arXiv.

Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D, Sun K, Butler K, Ezzedine K; TRuE V Study Group. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022 Oct 20;387(16):1445–1455. doi:10.1056/NEJMoa2205809

Downloads

Published

2025-06-12

Issue

Section

Review Article